#Cardiovascular drugs and #COVID-19 clinical outcomes: A living systematic review and meta-analysis

The aim of this study was to continually evaluate the association between cardiovascular drug exposure and COVID-19 clinical outcomes (susceptibility to infection, disease severity, hospitalization, hospitalization length, and all-cause mortality) in patients at risk of/with confirmed COVID-19. MethodsEligible publications were identified from more than 500 databases on 1 November 2020. One reviewer extracted data with …

Continue reading #Cardiovascular drugs and #COVID-19 clinical outcomes: A living systematic review and meta-analysis

The noradrenergic agent reboxetine plus antimuscarinic hyoscine butylbromide reduces sleep #apnoea severity: A double-blind, placebo-controlled, randomised crossover trial

Recent animal and human physiology studies indicate that noradrenergic and muscarinic processes are key mechanisms that mediate pharyngeal muscle control during sleep. The noradrenergic agent reboxetine combined with the anti-muscarinic hyoscine butylbromide has recently been shown to improve upper airway function during sleep in healthy individuals. However, whether these findings translate to the clinically relevant …

Continue reading The noradrenergic agent reboxetine plus antimuscarinic hyoscine butylbromide reduces sleep #apnoea severity: A double-blind, placebo-controlled, randomised crossover trial